Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
537.3 USD | -0.45% | +1.10% | +13.93% |
Apr. 26 | HCA beats first-quarter profit estimates on higher patient admissions | RE |
Apr. 25 | Elevance Health Insider Sold Shares Worth $10,832,155, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Elevance Health, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Elevance Health, Inc.
Mizuho Securities | |
TD Cowen | |
UBS | |
Bernstein | |
Leerink Partners | |
Jefferies & Co. | |
Goldman Sachs | |
RBC Capital Markets | |
Truist Securities | |
Wells Fargo Securities | |
Barclays | |
Cantor Fitzgerald | |
Stephens Inc. | |
Zacks Investment Research | |
JPMorgan Chase | |
Nephron Research | |
Morgan Stanley | |
Deutsche Bank Securities | |
Wolfe Research | |
Loop Capital | |
Morningstar | |
SVB Securities LLC | |
Credit Suisse | |
BofA Securities | |
Cowen | |
SVB Leerink | |
Argus | |
BMO Capital | |
Seaport Global Securities |
EPS Revisions
- Stock Market
- Equities
- ELV Stock
- Consensus Elevance Health, Inc.